Haemonetics to Report Next Week: Wall Street Foresees Earnings Growth
October 29, 2023
☀️Trending News
Haemonetics Corporation ($NYSE:HAE) is a global healthcare company that specializes in blood and plasma technologies. They offer a range of products and services for blood and plasma collection, therapeutic apheresis, hematology, immunology, cell therapy, and more. The company has a broad portfolio of innovative products and services for customers in the healthcare industry. Ahead of the next week’s first quarter earnings report, Wall Street analysts are predicting that Haemonetics will report an increase in earnings from the previous quarter. Analysts believe that the company’s strong performance in its core business and its successful entry into new markets should result in increased earnings.
In addition, they expect the company’s ongoing investments in research and development to bear fruit in the form of new products that can help drive future growth. Haemonetics has also been successful in reducing its operating costs, which should help the company deliver improved profits. These positive indicators have caused analysts to be bullish on the stock with many predicting that Haemonetics could achieve long-term success with its current strategy. Investors should keep an eye on the company’s upcoming earnings report to get a better sense of how well Haemonetics is performing. If Wall Street’s predictions hold true, the stock could rally in the days following the report.
Earnings
Wall Street is expecting HAEMONETICS CORPORATION to report impressive earnings next week. The company’s FY2024 Q1 earnings report as of June 30, 2021 showed 228.53M USD in total revenue and a net income loss of 4.45M USD. This marked a 12.6% decrease in total revenue and a 122.4% decrease in net income compared to the previous year.
Despite this, HAEMONETICS CORPORATION’s total revenue has grown over the last three years from 228.53M USD to 311.33M USD. Investors are hoping that the company will be able to exceed this growth in their upcoming earnings report.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Haemonetics Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 1.22k | 136.57 | 11.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Haemonetics Corporation. More…
| Operations | Investing | Financing |
| 250.15 | -100.83 | -77.57 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Haemonetics Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.96k | 1.1k | 17.05 |
Key Ratios Snapshot
Some of the financial key ratios for Haemonetics Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 10.8% | 14.7% |
| FCF Margin | ROE | ROA |
| 14.4% | 13.3% | 5.7% |
Stock Price
This represents a notable increase, and is a sign that investors are confident about the company’s future performance. Analysts have been bullish on Haemonetics’ outlook lately, and this week’s earnings report could provide further insight into the company’s financial health. Live Quote…
Analysis
GoodWhale performed an in-depth analysis of HAEMONETICS CORPORATION‘s wellbeing. According to Star Chart, HAEMONETICS CORPORATION is classified as a ‘gorilla’, suggesting that the company is capable of achieving stable and high revenue or earning growth due to its strong competitive advantage. This makes it attractive to investors who are looking for a reliable way to make money in the long term. Furthermore, HAEMONETICS CORPORATION has a high health score of 9/10. This indicates that the company has sustainable cashflows and debt, making it capable of sustaining its future operations even during times of crisis. In terms of performance, HAEMONETICS CORPORATION is strong in growth and profitability, but only medium in asset and weak in dividend. This could suggest that the company is focused more on short-term gains than on long-term stability. More…
Peers
The company has a wide range of products, including plasma collection systems, platelet and plasma pheresis systems, and whole blood collection systems. Haemonetics Corp. also provides services related to blood and plasma collection, such as plasma processing and storage, platelet and white blood cell processing, and whole blood processing. The company has a strong presence in the United States, Europe, Asia, and Australia. Merit Medical Systems Inc, Lagis Enterprise Co Ltd, StatSure Diagnostic Systems Inc are some of the major competitors of Haemonetics Corp.
– Merit Medical Systems Inc ($NASDAQ:MMSI)
Medtronic is a medical device company that develops and manufactures a wide range of products, from pacemakers to artificial hearts. The company has a market cap of $3.9 billion and a return on equity of 4.51%. Medtronic’s products are used by millions of people around the world, and the company is a leading provider of medical devices and services.
– Lagis Enterprise Co Ltd ($TPEX:6730)
Lagis Enterprise Co Ltd is a publicly traded company with a market capitalization of 1.02 billion as of 2022. The company has a return on equity of 12.12%. Lagis Enterprise Co Ltd is a diversified holding company that operates in a variety of industries, including construction, real estate, hospitality, and retail. The company has a strong presence in Taiwan and China, and its products and services are also available in North America, Europe, and Asia.
– StatSure Diagnostic Systems Inc ($OTCPK:SSUR)
StatSure Diagnostic Systems Inc is a company that manufactures and sells diagnostic products and services. The company has a market cap of 107.06k as of 2022 and a Return on Equity of 15.2%. The company’s products and services are used by healthcare professionals to diagnose and treat patients.
Summary
Haemonetics Corporation, a leading global healthcare company, is expected to report strong earnings growth next week. Analysts anticipate that the company’s third quarter financials will demonstrate solid improvements in revenue and profit margins. Analysts also predict that the company’s strong focus on cost savings and operational efficiencies will continue to drive higher returns for investors.
Additionally, the company’s new product releases and strategic partnerships are expected to further enhance its competitive advantage in the market. Overall, investors should continue to remain positive and optimistic about the company’s potential in the long-term as it continues to maintain financial stability and growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
